Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAIN-GP: High-CBD Product for Gynecologic Pain
NCT07728695Phase 2Recruiting
- Start
- Sep 2026
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cannabidiol in endometriosis, adenomyosis and pelvic inflammatory disease (PID) (3 arms). Primary endpoints: Quantification of parent CBD and its primary metabolites, 7-COOH-CBD and 7-OH-CBD, as well as metabolite-to-parent drug exposure ratios (MPR) at 7 days, Inflammatory markers at 7 days and 1 more. Started Sep 2026; status: recruiting.
02
Drugs
cannabidiol
03
Conditions
endometriosisadenomyosispelvic inflammatory disease (PID)
Beyond the preview
Go deeper on NCT07728695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07728695.